Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Adults With and Without Androgenetic Alopecia

Inclusion Criteria (Major):

• Participants must be overtly healthy, as determined by medical evaluation, which includes a review of medical and surgical history, physical examination, and a 12-lead ECG.

• Must have normal ranges for hematology, clinical chemistry, coagulation tests, and urine analysis parameters

• Participants, male and female, must be willing to avoid pregnancy for the duration of the trial.

• Participants must be capable of giving signed informed consent

• Participants must have no signs or symptoms of active or latent tuberculosis (TB),

Additional Inclusion criteria for patients with AGA:

• Diagnosis of AGA with a Norwood-Hamilton Scale III vertex to V pattern.

• Willing to clip target hair area for analysis and avoid scalp pigmentation products.

• Willingness to maintain approximately the same hair length at each study visit

Exclusion Criteria (Major):

• History or presence of cancer, except for basal cell carcinoma or cervical dysplasia successfully treated with no recurrence for ≥90 days before screening.

• History of liver disease, Gilbert's syndrome, or abnormal liver function tests (e.g., ALT, AST, or bilirubin > ULN) at screening

• Systolic blood pressure ≤90 or ≥140 mmHg, diastolic BP ≤40 or ≥90 mmHg, pulse rate <40 or >100 bpm

• Positive test for HIV, hepatitis B (HBV), or hepatitis C (HCV).

• Recent blood donation

• Any clinically significant psychiatric disorder

• Pregnant or breastfeeding females or those planning pregnancy during the study.

• History of postpartum depression, perimenopausal mood instability, or estrogen withdrawal syndrome

Additional Exclusion criteria for participants with AGA undergoing hair assessments:

•

Prior use of hair loss treatments:

1. Topical minoxidil within 3 months before screening.

2. Oral minoxidil other hair growth stimulators within 6 months before screening.

3. Finasteride within 6 months before screening

4. Dutasteride within 12 months before screening.

• Use of GLP-1 receptor agonists (e.g., semaglutide, liraglutide, dulaglutide, exenatide, tirzepatide, or similar agents) within 3 months prior to screening

• History of hair transplantation or other major scalp procedures or planned procedures during the study.

• Use of hair extensions, wigs, hairpieces, weaves, or any other artificial hair enhancement methods within 30 days prior to screening and throughout the study.

• History of clinically significant dermatologic disease of the scalp that could interfere with hair assessments or target area imaging